Generalised Myasthenia Gravis

We are committed to meeting the needs of people with generalised myasthenia gravis (gMG) by exploring new approaches for rare neurological diseases.


Generalised myasthenia gravis (gMG) is a rare, chronic, autoimmune disease that breaks down the communication between nerves and muscles, leading to muscle weakness that worsens with exertion and improves with rest. It is most common in women below their 40s and men over 60 years old. 

People with gMG may experience any of the following core symptoms: ocular symptoms (drooping eyelids, double vision),  difficulties with facial expression, chewing and swallowing, speaking,  weakness of the arms,  legs and neck resulting in limited mobility, shortness of breath, and in most extreme cases, respiratory failure (myasthenic crisis). Often diagnosis of people with gMG is delayed by months, or even years, due to the varying nature of symptoms and overlapping symptoms with other conditions.

The majority of people with gMG do not achieve stable remission with currently available treatments.


At Roche, we are exploring new approaches to meet the needs of people living with chronic, rare neurological diseases like gMG.


Understanding Generalised Myasthenia Gravis (gMG)

Discover more

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeCovid-19Pharma solutionsRoche careersMedia libraryAnnual Report 2023Privacy policyLegal statement